Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers 2014

Shannon Stott's Biography

Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

Professor Stott is a Mechanical Engineer that has been working at the interface of technology and medicine. She has an extensive background in microfluidics, optics, and tissue engineering, with a focus on their applications in clinical medicine. As a postdoctoral fellow, she invented the herringbone circulating tumor cell chip (HBCTC-Chip) a device that can successfully capture extremely rare cancer cells circulating in the blood stream cancer patients. Manipulating blood flow for the isolation and separation of biological components has been a hallmark of her work and recent efforts include using nanofluidics to separate extracellular vesicles and nucleic acids from patient samples. The overriding goal of the Stott Laboratory is to use all of these technologies and techniques to improve patient lives through early diagnosis and a greater understanding of how cancer spreads and kills. Dr. Stott has a particular interest in brain tumors and the potential impact of a blood biopsy for adult and pediatric patients.

Shannon Stott Image

Microfluidic Isolation of Microvesicles from Serum in Glioblastoma

Tuesday, 25 March 2014 at 16:00

Add to Calendar ▼2014-03-25 16:00:002014-03-25 17:00:00Europe/LondonMicrofluidic Isolation of Microvesicles from Serum in GlioblastomaCirculating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts,

Microvesicles (MVs) released from cancer cells into the bloodstream contain genetic information about the primary tumor.  These MVs have the potential to be used to guide treatment in glioblastoma patients, but can be challenging to reliably assay due to the heterogeneous population of MVs released from normal cells.  We have taken a microfluidic approach to isolate these tumor derived MVs from human serum, using affinity based capture. Specifically, a microfluidic chaotic mixer is used to direct the MVs to the antibody coated surface of the device. This approach increases our sensitivity of detection of oncogenic mutations, while being cost effective.  Our MV capture and subsequent RNA analysis was validated using tumor MVs from a glioblastoma cell line spiked into healthy human serum. Our data demonstrates that tumor-derived MVs can be selectively captured from serum, providing a  less invasive method to obtain genetic information about the patient’s tumor.

Add to Calendar ▼2014-03-24 00:00:002014-03-25 00:00:00Europe/LondonCirculating Biomarkers 2014Circulating Biomarkers 2014 in Boston, Massachusetts, USABoston, Massachusetts,